Search results (37)
« Back to PublicationsEstablishing a consensus definition of VEXAS flare for clinical research.
Weeks LD. et al, (2026), Rheumatology (Oxford), 65
Low-risk MDS-A spotlight on precision medicine for SF3B1-mutated patients.
Burke S. et al, (2025), Hemasphere, 9
Multi-organ abnormalities assessed by a single MRI scan in individuals with blood cancer.
Reed S. et al, (2024), Eur J Intern Med, 128, 150 - 152
Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
Chowdhury O. et al, (2021), Br J Haematol, 194, 1010 - 1015
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
Chowdhury O. et al, (2021), Leukemia, 35, 1197 - 1202
Evaluation of the detection of B-cell clonal lymphoproliferative disorders by flow cytometry or cytological analysis in lymph node aspirates obtained by endobronchial ultrasound
Lomas O. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 93 - 94
Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide
Chowdhury O. et al, (2018), BLOOD, 132
Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.
Mead AJ. et al, (2017), J Exp Med, 214, 2005 - 2021
Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia.
Watson AS. et al, (2015), Cell Death Discov, 1
Erratum to Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo, [Cancer Cell, 25, 2014, 794-808]
Woll PS. et al, (2015), Cancer Cell, 27, 603 - 605
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Svensson T. et al, (2014), Eur J Haematol, 93, 439 - 445
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine
Svensson T. et al, (2014), European Journal of Haematology, 93, 439 - 445